India, Nov. 21 -- Natco Pharma announced conclusion of US FDA Inspection at its Manali, Chennai, Active Pharmaceutical Ingredients (API) Unit. The inspection was conducted from 17 - 21 November 2025.On conclusion of the inspection, the Company received seven observations in the Form-483. The Company believes that the observations are procedural in nature. The Company is confident to address these observations comprehensively.
Published by HT Digital Content Services with permission from Pivotal Sources....